Skip to Content
🌐Ship toSelect country

Saypha Lips Lidocaine - 1 x 1,0ml

Saypha Lips Lidocaine is a Croma-Pharma cross-linked hyaluronic acid filler (23mg/ml HA, 0.3% lidocaine) specifically formulated for lip augmentation, designed to define the vermilion border, reduce vertical lip lines and add natural-looking volume. A postmarket randomised clinical study (114 patients) found high patient satisfaction both immediately and at 6-18 months post-treatment. For use by licensed, trained medical professionals only.

48.00 € 48.00 €
  • Brand
Terms and Conditions

Shipping: 
DHL EXPRESS SHIPPING (EU) — approx. 2-3 working days
STANDARD SHIPPING (EU) — approx. 7-10 working days
Select your delivery country in the header to check availability for your destination.
Category Fillers Brand Saypha
SKU A4806 Share
Treatment Areas LipsMouth
Tags Cross-Linked Hyaluronic AcidFine LinesHyaluronic AcidLidocaine

Saypha Lips is the lip-specific formulation within the Saypha range, designed to add volume and shape to the lips while remaining soft to the touch. Part of the Saypha range from Croma-Pharma, an Austrian manufacturer with over four decades of experience in hyaluronic acid production for the aesthetics market. It is pre-mixed with lidocaine for a more comfortable injection experience.

CONCENTRATION

  • Cross-linked hyaluronic acid (Croma-Pharma)
  • Lidocaine hydrochloride

THE PACK INCLUDES

  • 1 x 1.0ml Syringe

STORAGE CONDITIONS

  • Store between 2°C and 25°C
  • Do not freeze

RESULTS & DURATION

Results typically last 6-9 months.

INDICATIONS

  • Lip volume loss
  • Fine lines around the mouth

TREATMENT AREAS

  • Lips
  • Mouth

Saypha Lips is injected into the lip tissue using linear threading or micro-bolus technique, according to the desired shape and volume.

Final results are assessed after 1-2 weeks once any swelling has resolved.

  • Pregnancy or breastfeeding
  • People under the age of 18
  • Active infection or inflammation at the treatment site (including cold sores)
  • Known hypersensitivity to hyaluronic acid or lidocaine
  • Patients prone to hypertrophic scarring
  • Autoimmune diseases affecting the skin